In this issue of CRM, Petrov et al. have provided further evidence of the safety and efficacy of catheter-based renal denervation (RDN) for the treatment of poorly-controlled hypertension. These results support the concept that the completeness of the renal denervation plays an important role in achieving meaningful blood pressure (BP) lowering. Indeed, the results from their study suggest that with a monopolar catheter, with 20.4±3.9 ablations in the main and branch vessels in humans (“Y” technique), one can achieve substantial, and clinically meaningful, reductions in office and ambulatory systolic BP.